Potential of Autologous Immunologic Effector Cells for Prediction of Progression of Disease in Patients with Chronic Myelogenous Leukemia

References

• Krance R., Heslop H. E., Mahmoud H., Ribeiro R., Douglass E., Hurwitz C., Santana V., Kun L., Horowitz M. M., Brenner M K. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylpredisolone for acute GVHD prophylaxis following allogenic BMT from HLA-identical sibling donors. Bone Marrow Transplant 1993; 11(1)33–36
   PubMed Web of Science ®Google Scholar
• Nadler L. M., Takvorian T., Botnick L., Bast R. C., Fin-Berg R., Hellman S., Canellos G. P., Schlossman S. F. Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 1984; 2(8400)427–431
   PubMed Web of Science ®Google Scholar
• Treleaven J. G., Kemshead J. T. Removal of tumor cells from bone marrow: An evaluation of the available techniques. Hematology and Oncology 1985; 3(1)65–75
   PubMed Web of Science ®Google Scholar
• Macintyre E. A. The use of monoclonal antibodies for purging autologous bone marrow in lymphoid malignancies. Clinics in Haematology 1986; 15(1)249–267
   PubMedGoogle Scholar
• Santos G. W., Colvin O. M. Pharmacological purging of bone marrow with reference to autografting. Clinics in Haematology 1986; 15(1)67–83
   PubMedGoogle Scholar
• Yeager A. M., Kaizer H., Santos G. W., Saral R., Colvin O. M., Stuart R. K., Braine H. G., Burke P. J., Ambinder R. F., Burns W. H., et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex-vivo marrow treatment with 4-hydroperoxycyclo-phosphamide. New England Journal of Medicine 1986; 315(3)141–147
   PubMed Web of Science ®Google Scholar
• Negrin R. S., Kiem H. P., Schmidt-Wolf I. G. H., Blume K. G., Cleary M. L. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 1991; 77(3)654–660
   PubMed Web of Science ®Google Scholar
• Feeney M., Knapp R. C., Greenberger J. S., Bast R. C. Elimination of leukemic cells from rat bone marrow using antibody and complement. Cancer Research 1981; 41: 3331–3335
   PubMed Web of Science ®Google Scholar
• Trigg M. E., Poplack D. G. Transplantation of leukemic bone marrow treated with cytotoxic antileukemic antibodies and complement. Science 1982; 217(4556)259–261
   PubMed Web of Science ®Google Scholar
• Andrews R. G., Torok-Storb B., Bernstein I. D. Myeloid associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62(1): 124–132
   Web of Science ®Google Scholar
• Vitetta E. S., Krolick K. A., Uhr J. W. Neoplastic B cell targets for antibody-ricin A chain immunotoxins. Immunological Revue 1982; 62: 159–183
   PubMed Web of Science ®Google Scholar
• Ball E. D., Mills L. E., Coughlin C. T., Beck J. R., Cornwall G. G. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid cell-specific monoclonal antibodies. Blood 1986; 68(6)1311–1315
   PubMed Web of Science ®Google Scholar
• Takvorian T., Canellos G. P., Ritz J. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. New England Journal of Medicine 1987; 316(24)1499–1505
   PubMed Web of Science ®Google Scholar
• Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon lysis of killer cells with potent antitumor cell activity. Journal of Experimental Medicine 1982; 174(1)139–149
   Google Scholar
• Kaneko T., Fusauchi Y., Kakui Y., Masuda M., Akahoshi M., Teramura M., Motoji T., Okumura K., Mizoguchi H., Oshimi K. A bispecific antibody enhances cytok-ine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 1993; 81(5): 1333–1341
   Web of Science ®Google Scholar
• Lu P. H., Negrin R. S. A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice. J Immunol 1994; 153(4)1687–1696
   PubMed Web of Science ®Google Scholar
• Lozzio C. B., Lozzio B. B. Chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321–334
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf I. G. H., Aihara M., Negrin R. S., Blume K. G., Chao N. J. Lymphokine-activated killer cell activity after cryopreservation. Journal of Immunological Methods 1989; 125(1–2)185–189
   PubMed Web of Science ®Google Scholar
• Aihara M., Aihara Y., Schmidt-Wolf I., Sikic B. I., Blume K. G., Chao N. J. A combined approach for purging multidrug resistant leukemic cell lines in bone marrow, using a monoclonal antibody and chemotherapy. Blood 1991; 77(9)2079–2084
   PubMed Web of Science ®Google Scholar
• Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Annals of Biochemistry 1987; 162(1)156–159
   Web of Science ®Google Scholar
• Neubauer A., De Kant E., Rochlitz C., Laser J., Zanetta A. M., Gallardo J., Oertel J., Herrmann R., Huhn D. Altered expression of the retinoblastoma susceptibility gene in chronic lymphocytic leukemia. British Journal of Haematology 1993; 85(3)498–503
   PubMed Web of Science ®Google Scholar
• Neubauer A., He M., Schmidt C. A., Huhn D., Liu E. T. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. leukemia 1993; 7(4)593–600
   PubMed Web of Science ®Google Scholar
• Dunbar C. E., Stewart F. M. Separating the wheat from the chaff: Selection of benign hematopoietic cells in chronic myeloid leukemia. Blood 1992; 79(5)1107–1110
   PubMed Web of Science ®Google Scholar
• Trinchieri G., Perussia B. Human natural killer cells: Biologic and pathologic aspects. Laboratory Investigations 1984; 50(5)489–513
   PubMed Web of Science ®Google Scholar
• Herberman R. B., Reynolds C. W., Ortaldo J. R. Mechanism of cytotoxicity by natural killer (NK) cells. Annual Revue in Immunology 1986; 4: 651–680
   PubMed Web of Science ®Google Scholar
• Imamura N., Kuramoto A. Natural killer activity is not dependent on the CD3-Ti T-cell receptor antigen complex. Blood 1988; 72(5)1837–1838
   PubMed Web of Science ®Google Scholar
• Oblakowski P., Bello-Fernandez C., Reittie J. E. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood 1991; 77(9)1996–2001
   PubMed Web of Science ®Google Scholar
• Hauch M., Gazzola M. V., Small T., Bordignon C., Barnett L., Cunningham I., Castro Malaspinia H., O'Reilly R. J., Keever C. A. Anti-leukemia potential of interleu-kin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75(11)2250–2262
   PubMed Web of Science ®Google Scholar
• Pawelec G., Ehninger G., Schmidt H., Muller C., Buhring H. J., Reutter M., Busch F. W. Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-a-treated chronic myelogenous leukaemia patients. Cancer Immunology and Immunotherapy 1990; 32(3)167–172
   PubMed Web of Science ®Google Scholar
• Scheffold C., Brandt K., Johnston V., Lefterova P., Degen B., Schontube M., Huhn D., Neubauer A., Schmidt-Wolf I. G.H. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 1995; 15(1)33–39
   PubMed Web of Science ®Google Scholar
• Santucci M. A., Butturini A., Gale R. P. Can long-term bone marrow culture eliminate leukemia cells?. Leukemia and Lymphoma 1990; 3: 87
   PubMed Web of Science ®Google Scholar